PharmaGap fka GAP

[Ed Monton]

OTTAWA,ONTARIO--(Marketwire - June 24, 2010) - PharmaGap Inc. (TSXVENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") todayannounced 80% average growth inhibition (at 20 micromolar dose) in invitro testing of its lead cancer drug GAP-107B8 in Ocular andCutaneous Melanoma at Memorial Sloan-Kettering Cancer Center (MSKCC).

"In addition to seeing these strong in vitro resultsin melanoma, we are very excited to learn that the test program atMSKCC will proceed to animal tests, and I anticipate results from thesetests during our 3rd quarter", said, President RobertMcInnis.

"We are seeing promising results in the melanoma cell linepanel, and I am excited to be continuing with further testing, both invitro and in animal models, to explore the potential for this newdrug compound," stated Dr. Gary Schwartz, chief of the Melanoma andSarcoma Service at Memorial Sloan-Kettering Cancer Center.

In these tests, GAP-107B8 was tested in cell proliferationassays in 6 Ocular Melanoma and 4 Cutaneous Melanoma human cancer celllines with established cell signaling profiles in order to generatefurther understanding of GAP-107B8's efficacy in slowing proliferation,its time course of effect in cells, dose level response patterns, andinhibition of known cell signaling targets.

In the dose levels of 10, 15, and 20 micromolars (um),GAP107B8 slowed cell growth by, 29%, 62%, and 80% (average across allcell lines), showing a clear effect in slowing cancer cell proliferationand a clear effect of different dose levels.

Image analysis of cells over time showed biological effectsin cells in as early as 15 minutes, and inhibitory effect on signalingpathways was observed to be time-dependent and observed as early as 2hours following treatment. Inhibition of known cancer-related signalingpathways was observed in mTOR, MAPK, and PKC pathways (alpha and delta).

This in vitro test program will continue over thenext few weeks with additional analysis of GAP-107B8's mechanism onautophagic cell death, cell cycle effects in order to elucidateadditional mechanism of action information, and testing of the drugagainst normal, non-cancer cells in order to continue to establish thesafety profile of the drug.

"A series of tests are underway to provide the basis for selection of the cancer target for clinical trial application. I expect results from the pharmacokinetics program at the National ResearchCouncil, carried out in conjunction with Tandem Labs, to be availablenext week. I will be outlining the company's program to licensing at the Annual General Meeting later today, and we will report further on thatprogram in the next few days", Mr. McInnis said.

About PharmaGap Inc.

PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is abiotechnology company with a core focus on developing novel peptidetherapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is anovel peptide drug that has been shown to be highly cytotoxic tonumerous cancer types, including chemo-resistant cancers, in vitro.For more information on PharmaGap please visit the Company's website atwww.pharmagap.com.

Note: Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracy ofthis release. No Securities Commission or other regulatory authorityhaving jurisdiction over PharmaGap has approved or disapproved of theinformation contained herein. This release contains forward lookingstatements that may not occur or may change materially.

For more information, please contact
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-955
[e-mail]
or
PharmaGap Inc.
Martin Tremblay
IR Consultant
514-351-3736
[e-mail]
Clickhere to see all recent news from this company